Detail akcie Senti Bioscis Rg online

Business Summary: Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Senti Biosciences Inc revenues was not reported. Net loss decreased 10% to $47M. Lower net loss reflects Biotechnology & Medical Research segment loss decrease of 62% to $16.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$11.41 to -$2.25.